Frankfurt am Main, Germany

Franceska Fischer


 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):

Title: Franceska Fischer: A Trailblazer in Pharmaceutical Innovations

Introduction: Franceska Fischer, an accomplished inventor based in Frankfurt am Main, Germany, has made significant contributions to the field of pharmaceuticals. With one patent to her name, Franceska has demonstrated her expertise and commitment to advancing healthcare solutions.

Latest Patents: Franceska's notable patent, titled "Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use," pertains to crystalline hydrates designed to address important medical issues. Specifically, the invention offers a compound suitable for use as an antidiabetic, enhancing the treatment options available for diabetes care. The patent describes compounds with a formula where "n" ranges from 2.1 to 2.5, emphasizing the intricacies of this innovative treatment.

Career Highlights: Franceska is currently employed at Sanofi, a leading global biopharmaceutical company known for its dedication to research and innovation in medical solutions. Her role within such a prestigious organization underscores her position as a valuable contributor to the scientific community, and her work reflects her dedication to improving patient outcomes through innovative inventions.

Collaborations: Throughout her career, Franceska has collaborated with talented colleagues, including David Rigal and Bernd Becker. These partnerships have fostered a collaborative environment that promotes creativity and innovation in their research efforts. Together, they have driven forward-thinking projects that hold promise for the advancement of pharmaceutical sciences.

Conclusion: Franceska Fischer is a remarkable inventor whose work is reshaping the pharmaceutical landscape. Her patent on crystalline heteroaromatic fluoroglycoside hydrates exemplifies her commitment to innovation and improving healthcare. As she continues her journey at Sanofi, her contributions will undoubtedly pave the way for new therapeutic options that benefit patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…